GoldenGolden
Advanced Search
Twist Bioscience

Twist Bioscience

A DNA synthesis company using a next-generation silicon-based technology platform.

Twist Bioscience was founded in 2013 by Emily Leproust to commercialize a high-throughput semiconductor-based DNA synthesis technology. The company supplies DNA for research and commercial applications of genetic engineering, and is developing additional markets for applications including digital data storage and DNA origami-based biomaterials and nanostructures.

Twist Bioscience can achieve 1,000x improvements in DNA production density by scaling down from the traditional 96-well plate to tiny micro-wells and channels on a silicon chip of the same area. Throughput is greatly increased because semiconductor-based technology allows the chemical reactions necessary for DNA synthesis to be scaled down by a factor of 1,000,000. Twist Bioscience is able to produce 9,600 genes on a single silicon chip using their technology; compared to 1 gene being produced on the same amount of space using traditional DNA synthesis technologies.

In the video below, CEO of Twist Bioscience Emily Leproust, explains the innovations in DNA synthesis technology.

Applications of Synthetic DNA

Application
Description

Chemical Production

Reduce cost of introducing new genes into microorganisms that produce chemicals

Crop Optimization

Improve the throughput and reduce the cost of genetically engineering crops

Drug Discovery

Enable more rapid, cheaper protein engineering for drug discovery

Functional Genomics

Lower cost of identifying disease gene targets

Genome Editing

Reduce cost and increase efficiency of CRISPR technology

Twist Bioscience is providing DNA synthesis to Inovio Pharmaceuticals for its research developing a vaccine against the 2019-nCoV coronavirus, renamed SARS-CoV-2, with the disease called COVID-19 (coronavirus disease).

Products and services

Twist Bioscience offers a variety of DNA synthesis products and services that are summarized below.

Clonal genes​

Next generation sequencing (NGS) verified gene clones with no type II S restriction sequences and custom vector onboarding with verification. There is currently a lower limit of 10+ genes (no upper limit ) to place an order that will be ready within 20 business days.

Product details
Information

Custom cloning

$50/construct

Minimum order

10 genes

Price

9¢/base

Size

0.3-3.2 kb

Turnaround time

20 business days

Vector Options

Twist catalog or custom vector

Combinatorial libraries

Using ​combinatorial libraries for focused mutagenesis offers more flexibility and better representation than degenerate approaches. Specific codons may be excluded, codon ratio can be controlled, and all libraries are NGS verified.

Product details
Information

Delivery and yield

Single tube, 1 ug total

Price

Project-dependent

Product format

Linear double-stranded DNA

Turnaround time

4-6 weeks, project dependent

DNA digital data storage

DNA is being developed as a storage medium for digital data. Twist Bioscience is working with Microsoft and the University of Washington to improve data storage using DNA, and have published research demonstrating high-fidelity storage and random-access retrieval of over 200 MB of data, including an OK Go music video. As the technology matures, DNA could offer a high-density, low-energy, long-term, and secure digital data storage solution. Twist Bioscience explains their work on DNA data storage in their white paper.

Gene fragments​

Gene fragments are non-clonal, and can be used for several downstream cloning methods for assembly into bigger genes or pathways. The error rate on gene fragment production is approximately 1:3000 base pairs.

Product details
Information

Max size

0.3-1.8kb

Minimum order

10 genes

Price

7¢/base

Turnaround time

7-10 business days

Yield

200ng/fragment

Oligo pools​

Oligo pools are made to be diverse collections of oligonucleotides and can be used for applications such as creation of CRISPR sgRNA libraries high-throughput reporter essays. Oligo pools are made to be highly uniform and accurate for maximal oligo representation and have an error rate of approximately 1:1000 nucleotides (nt).

Product details
Information

Minimum order

2,000

Oligo length

Up to 200 nt

Oligo pool size

2,000 to 1,000,000 oligos

Price

Quote

Turn around time

10 days

Yield

>0.1 fmol of each oligo

Site saturation libraries​

Site saturation libraries are precise and diverse when compared to traditional directed mutagenesis techniques. Each saturation library is verified using NGS technology. They come free from unwanted codons and can be made to have specific codon ratios.

Product details
Information

Delivery and yield

Single tube, 1-2ug total. 96 plate well, 1/2 positions per well of 50 ng each. 384 well plate, 1/2 positions per well of 50 ng each.

Minimum order

48 variants

Price

$50/position

Product format

Linear double-stranded DNA

Turnaround time

3-4 weeks, project dependent

Twist human core exome kit​

The Twist human core exome kit is a DNA probe target enrichment kit. It comes with modular high performance DNA probes designed to uniformly and accurately capture sequence depth. The modular kit is simple to integrate into existing lab protocols due to its has many customization options.

Alternatives and lawsuits

The turnaround time for orders is still relatively long compared to other lab-based methods, especially for smaller amounts of DNA. Therefore, in certain instances it is more reasonable for researchers and companies to utilize traditional cloning methods depending on the genes needed for experiments. Slow turnaround time for smaller orders is the primary reason Ginkgo Bioworks acquired Gen9, which brought that function in-house.

In 2016 Agilent filed a lawsuit against Twist Bioscience alleging Emily Leproust, a former Agilent employee, stole trade secrets developed by the company to start the DNA synthesis startup.

Funding
Government grants/awards

On May 27th, 2014 Twist Bioscience received $5.1 million dollars in funding from the Defense Advanced Research projects Agency (DARPA). The contract was awarded to Twist Bioscience under DARPA's Living Foundries program.

Series A

On Feb 10 2014, Twist Bioscience received $9,100,000 in series A funding from Asset Management Ventures (AMV).

Series B

On May 27 2014, Twist Bioscience completed a $26,000,000 series B funding round. Investors include: DARPA, ARCH Venture Partners, Paladin Capital Group, Yuri Milner, and some undisclosed investors.

Series C

On June 10 2015, Twist Bioscience closed a $37,000,000 series C funding round. Investors include: Foresite Capital, ARCH Venture Partners, Paladin Capital Group, Venture Investors, Fidelity Management & Research, Illumina, Joby Pritzker, and Yuri Milner.

Series D

On March 27th 2017, Twist Bioscience closed a $61,000,000 series D funding round. Investors include: Foresite Capital, ARCH Venture Partners, Paladin Capital Group, Fidelity Management & Research, Illumina, Boris Nikolic, Cormorant Asset Management, WuXi Healthcare Ventures, Yuri Milner, Mérieux Développement, ARCH Overage Fund, Nick Pritzker, and Joby Pritzker.

Series E

On June 14th 2017, Twist Bioscience closed a $27,000,000 series E funding round. Investors include: Biomatics Capital, Reinet Fund S.C.A, F.I.S, NFT Investment Limited, KangMei Group, Bay City Capital, GF Xinde Life Science Investment Fund, 3W Partners Capital, and Ditch Plains Capital Management LP.

Private placement

On April 3rd 2018, Twist Bioscience received $50,000,000 in funding from private investors.

Partnerships
Desktop genetics

In June 2016, Twist Bioscience became partners with Desktop Genetics, a company using AI to create CRISPR screens. The partnership focuses on developing and integrating DNA synthesis tools to design research protocols that enhance gene editing research. Desktop Genetics works with their customers to design CRISPR sgRNA libraries for a cell line before sending this information to Twist Bioscience for sgRNA library synthesis. This partnership aims to reduce cost and improve efficiency of gene editing research.

BioBricks Foundation

In June 2017, the BioBricks foundation partnered up with Twist Bioscience on the Free Genes project, an initiative to create an open-source library of 10,000 genes that form biological parts important for synthetic biology. Twist Bioscience will be providing all the DNA that will be used for the project, and BioBricks will assemble a library of useful genes using its team and drawing on support from the scientific community. All genetic constructs created through this partnership will be made freely available to the public through the Open Material Transfer Agreement, which allows any recipient to use, modify, combine, copy, and redistribute the genes (in compliance with applicable biosafety and intellectual property laws).

Quintara Biosciences

In July 2017, Quintara Bioscience and Twist Bioscience became business partners, announcing they will be working together to create qBlock Gene Fragment and qGene DNA cloning services. Twist Bioscience will combine their silicon DNA synthesis technology with Quintara Bioscience's sequencing and cloning technologies to deliver gene fragment and cloning services.

Synbio Technologies

Twist Bioscience and Synbio Technologies became partners on July 11th, 2017. The partnership seeks to combine technologies being used at both companies, by offering DNA strands up to 70 kilobases in length. Twist Bioscience will synthesize DNA strands up to 3.2 kilobases in length before shipping them off to Synbio Technologies for completion. This partnership gives both companies more international presence: Twist Bioscience in located in San Francisco, and Synbio Technologies is in China, so by working together they plan to be able to offer improved DNA strand products that enhance scientific research for the diagnosis and treatment of disease.

Company Patents

Patent Description
Inventor
Status
Date
App/pub number

William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle, Cheng-Hsien Wu, Esteban Toro

Application

2016-02-11

WO2016022557A1

Cheng-Hsien Wu

Application

2016-11-17

US20160333340A1

Esteban Toro, Sebastian Treusch, Siyuan Chen, Cheng-Hsien Wu

Grant

2017-06-13

US9677067B2

William Banyai, Bill James Peck, Andres Fernandez, Siyuan CHEN, Pierre Indermuhle

Application

2015-05-28

WO2015021080A3

William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle, Eugene P. Marsh

Application

2016-10-27

US20160310927A1

Bill James Peck

Application

2017-03-23

US20170081716A1

Bill James Peck,Pierre Indermuhle, Eugene P. Marsh, Andres Fernandez, David Stern

Grant

2018-02-20

US9895673B2

Pierre F. Indermuhle, Eugene P. Marsh, Andres Fernandez, William Banyai, Bill J. Peck

Application

2016-08-11

US20160229884A1

Anthony Cox, Sebastian Treusch, Siyuan Chen

Application

2017-03-23

US20170081660A1

Mergers/acquisitions
Genome Compiler

On April 6th, 2016 Twist Bioscience acquired the Israeli software company Genome Compiler for an undisclosed price. Twist plans to use Genome Compiler's software developers and technology to build an an e-commerce platform that allows customers to create their own gene designs online before ordering, and to leverage their strong software development team for future projects.

Revenue

According to BCC Research, the overall market for synthetic biology products is expected to grow from $4.4 billion in 2017 to over $13.9 billion by 2022.

Twist serves 600 customers across the three areas of the synthetic biology market in a broad range of industries. Revenue was $20.5 million for the trailing 12 months ended June 30, 2018, and revenue in the quarter ended Sept. 30, 2018, the company's fiscal year end, is estimated to be between $8.0 million and $8.3 million. Ginkgo Bioworks is Twist Bioscience's largest customer, accounting for 32% of revenue.

Timeline

May 25, 2021
Twist Bioscience launches Enzymatic Fragmentation Library Preparation Kit for high uniformity, high-yield amplification, streamlined next generation sequencing workflow for targeted applications.
February 25, 2020
Twist Bioscience announces that it has initiated a collaboration with digital microfluidics developer Miroculus.
April 4, 2018
Private Placement Funding

On April 3rd, 2018 Twist Bioscience received $50,000,000 in funding from private investors.

April 2, 2018
Twist Bioscience raises a $50,000,000 venture round.
July 11, 2017
Synbio Technologies Partnership

​Twist Bioscience and Synbio Technologies became partners on July 11th, 2017. The partnership seeks to combine technologies being used at both companies, by offering DNA strands up to 70 kilobases in length. Twist Bioscience will synthesis DNA strands up to 3.2 kilobases in length before shipping them off to Synbio Technologies for completion. This partnership gives both companies more international presence, Twist Bioscience in located in France, and Synbio Technologies is in China, and by working together they are able to offer improved DNA strand products that enhance scientific research for the diagnosis and treatment of disease.

July 1, 2017
Quintara Biosciences Partnership

In July 2017, Quintara Bioscience and Twist Bioscience became business partners, announcing they will be working together to create qBlock Gene Fragment and qGene DNA cloning services. Twist Bioscience will combine their silicon DNA synthesis technology with Quintara Bioscience's sequencing and cloning technologies to deliver gene fragment and cloning services.

June 15, 2017
Series E Funding Round

June 14th, 2017 Twist Bioscience received $27,000,000 after completing their series E funding round. Investors include: Biomatics Capital, Reinet Fund S.C.A, F.I.S, NFT Investment Limited, KangMei Group, Bay City Capital GF Xinde Life Science Investment Fund, 3W Partners Capital, and Ditch Plains Capital Management LP.

June 14, 2017
Twist Bioscience raises a $27,000,000 venture round from 3W Partners, Bay City Capital, Biomatics Capital Partners, Ditch Plains Capital Management, FIS, Kangmei Pharmaceutical, NFT Investment and Reinet Investments.
June 1, 2017
Biobricks Foundation Partnership

In June 2017, the BioBricks foundation partnered up with Twist Bioscience to create a library of 10,000 genes that form biological parts important for synthetic biology. Twist Bioscience will be providing all the DNA that will be used for the project, and BioBricks will assemble a library of useful genes using its team and drawing on support from the scientific community. Everything created through this partnership is based on a Open Material Transfer Agreement that allows anyone to have free access to the genes.

April 28, 2017
Series D Funding Round

​On March 27th, 2017 Twist Bioscience received $61,000,000 after completing their series D funding round. Investors include: Foresite Capital. ARCH Venture Partners, Paladin Capital Group, Fidelity Management & Research, Fidelity Management and Research Company, Illumina, Boris Nikolic, Cormorant Asset Management, WuXi Healthcare Ventures, Fidelity Management, Yuri Milner, Merieux Developpement, ARCH Overage Fund, Foresite Capital Management, WuXi, Corporate Venture Fund, Nick Pritzker, and Joby Pritzker.

Page 1 of 3

Funding rounds

People

Name
Role
LinkedIn

Anthony Romeo

Employee

aviva gatt

Employee

Bill Peck

Billy Banyai

Boris Nikolić

Investor

Daniel Bibl

Employee

David Maddow

Employee

David Schnayer

Employee

Dominique Toppani

Employee

Emily Leproust

Founder, CEO

Eric Anschutz

Investor

Esteban Toro

Employee

Fay Xing

Investor

Gillian Jarvis

Employee

Hang Ngo

Employee

James Diggans

Employee

Josh Pollick

Attorney

Mark Daniels

Mesut Arik

Employee

Nikhil Haas

Employee

Omri Amirav-Drory

Employee

Patrick Finn

Patrick Weiss

Paula Green

Pierre Indermuhle

Employee

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Could Synthetic DNA Be the Next Tech Breakthrough?

Jennifer Alsever

Ginkgo Bioworks Triples the Size of DNA Supply Agreement with Twist Bioscience​

Christine Stevenson​

Twist Bioscience, Desktop Genetics Form CRISPR Partnership​

Staff Reporter

Twist Bioscience's $75 Million IPO Expected Next Week for Gene Synthesis Platform

Web

Twist Bioscience’s Partnership with Biobricks Foundation Accelerates Synthetic Biology Discovery

Twist Bioscience press release

UW, Microsoft and Twist Bioscience double down on DNA data storage experiments

Alan Boyle

Why the future will be written in DNA: An interview with Twist Bioscience's Bill Peck - SynBioBeta

Kevin Costa

Documentaries, videos and podcasts

Title
Date
Link

Custom CRISPR Screening Libraries WEBINAR

November 22, 2017

Emily Leproust Making DNA from Scratch​

August 2nd, 2017

​Writing DNA - Emily Leproust, CEO of Twist Bioscience

December 9th, 2016

Companies

Company
CEO
Location
Products/Services

Twist Bioscience

Clonal Genes

Twist Bioscience

Combinatorial Libraries

Twist Bioscience

Twist Human Core Exome Kit

Twist Bioscience

Gene Fragments

Twist Bioscience

Oligo Pools

Twist Bioscience ​

Site Saturation Libraries

News

Title
Author
Date
Publisher
Description
Alexandra Ames
August 17, 2021
TechCrunch
Solving the twin challenges of human and planetary health is the greatest task of our generation, and it also presents the greatest entrepreneurial opportunity in history which is why we've partnered with Mayfield to bring you an engineering biology track to Disrupt 2021 this September 21-23. Haven't secured your spot yet? Grab your ticket now [...]
Joel Khalili
June 28, 2021
TechRadar India
DNA has all the necessary attributes to solve the looming data crisis.
Dovetail Genomics LLC
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, today announced availability of its new line of...
Conor Hale
June 14, 2021
FierceBiotech
Twist Bioscience teamed up with Regeneron to deliver a sequencing test that can track genetic differences among global populations, for a better understanding of how diseases among different ethnicities.
Andrea Park
May 27, 2021
FierceBiotech
The series D will support further development of GenapSys' sequencing technology, which aims to offer a less expensive, more accessible alternative to other next-generation sequencing platforms.
BioSpace
May 25, 2021
BioSpace
Twist Bioscience Corporation (Nasdaq: TWST) today launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0 , a robust all-in-one solution designed to maximize accuracy and efficiency in library construction and amplification when conducting next-generation sequencing (NGS).
Mark Terry
May 14, 2021
BioSpace
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here's a look.
Mark Terry
May 14, 2021
BioSpace
Life science jobs are booming in several regions around the U.S. One is the Pacific Northwest, specifically Oregon; another is the Philadelphia area. Here's a look.
BioSpace
May 13, 2021
BioSpace
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its support of the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research .
BioSpace
April 28, 2021
BioSpace
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Vivlion GmbH, a company providing next-generation CRISPR gRNA libraries and screening services for the global R&D market, today announced a collaboration for the generation of gRNA libraries for CRISPR applications.
BioSpace
April 28, 2021
BioSpace
Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Vivlion GmbH, a company providing next-generation CRISPR gRNA libraries and screening services for the global R&D market, today announced a collaboration for the generation of gRNA libraries for CRISPR applications.
Lythgoe, K. A., Hall, M., Ferretti, L., de Cesare, M., MacIntyre-Cockett, G., Trebes, A., Andersson, M., Otecko, N., Wise, E. L., Moore, N., Lynch, J., Kidd, S., Cortes, N., Mori, M., Williams, R., Vernet, G., Justice, A., Green, A., Nicholls, S. M., Ansari, M. A., Abeler-Dörner, L., Moore, C. E., Peto, T. E. A., Eyre, D. W., Shaw, R., Simmonds, P., Buck, D., Todd, J. A., on behalf of the Oxford Virus Sequencing Analysis Group (OVSG), Connor, T. R., Ashraf, S., da Silva Filipe, A., Shepherd, J., Thomson, E. C., The COVID-19 Genomics UK (COG-UK) Consortium, Bonsall, D., Fraser, C., Golubchik, T.
April 16, 2021
Science
A year into the severe acute respiratory syndrome coronavirus 2 pandemic, we are experiencing waves of new variants emerging. Some of these variants have worrying functional implications, such as increased transmissibility or antibody treatment escape. Lythgoe et al. have undertaken in-depth sequencing of more than 1000 hospital patients' isolates to find out how the virus is mutating within individuals. Overall, there seem to be consistent and reproducible patterns of within-host virus diversity. The authors observed only one or two variants in most samples, but a few carried many variants. Although the evidence indicates strong purifying selection, including in the spike protein responsible for viral entry, the authors also saw evidence for transmission clusters associated with households and other possible superspreader events. After transmission, most variants fizzled out, but occasionally some initiated ongoing transmission and wider dissemination. Science , this issue p. [eabg0821][1] ### INTRODUCTION Genome sequencing at an unprecedented scale during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is helping to track spread of the virus and to identify new variants. Most of this work considers a single consensus sequence for each infected person. Here, we looked beneath the consensus to analyze genetic variation within viral populations making up an infection and studied the fate of within-host mutations when an infection is transmitted to a new individual. Within - host diversity offers the means to help confirm direct transmission and identify new variants of concern. ### RATIONALE We sequenced 1313 SARS-CoV-2 samples from the first wave of infection in the United Kingdom. We characterized within-host diversity and dynamics in the context of transmission and ongoing viral evolution. ### RESULTS Within-host diversity can be described by the number of intrahost single nucleotide variants (iSNVs) occurring above a given minor allele frequency (MAF) threshold. We found that in lower-viral-load samples, stochastic sampling effects resulted in a higher variance in MAFs, leading to more iSNVs being detected at any threshold. Based on a subset of 27 pairs of high-viral-load replicate RNA samples (>50,000 uniquely mapped veSEQ reads, corresponding to a cycle threshold of ~22), iSNVs with a minimum 3% MAF were highly reproducible. Comparing samples from two time points from 41 individuals, taken on average 6 days apart (interquartile ratio 2 to 10), we observed a dynamic process of iSNV generation and loss. Comparing iSNVs among 14 household contact pairs, we estimated transmission bottleneck sizes of one to eight viruses. Consensus differences between individuals in the same household, where sample depth allowed iSNV detection, were explained by the presence of an iSNV at the same site in the paired individual, consistent with direct transmission leading to fixation. We next focused on a set of 563 high-confidence iSNV sites that were variant in at least one high-viral-load sample (>50,000 uniquely mapped); low-confidence iSNVs unlikely to represent genomic diversity were excluded. Within-host diversity was limited in high-viral-load samples (mean 1.4 iSNVs per sample). Two exceptions, each with >14 iSNVs, showed variant frequencies consistent with coinfection or contamination. Overall, we estimated that 1 to 2% of samples in our dataset were coinfected and/or contaminated. Additionally, one sample was coinfected with another coronavirus (OC43), with no detectable impact on diversity. The ratio of nonsynonymous to synonymous ( dN/dS ) iSNVs was consistent with within-host purifying selection when estimated across the whole genome [ dN/dS = 0.55, 95% confidence interval (95% CI) = 0.49 to 0.61] and for the Spike gene ( dN/dS = 0.60, 95% CI = 0.45 to 0.82). Nevertheless, we observed Spike variants in multiple samples that have been shown to increase viral infectivity (L5F) or resistance to antibodies (G446V and A879V). We observed a strong association between high-confidence iSNVs and a consensus change on the phylogeny (153 cases), consistent with fixation after transmission or de novo mutations reaching consensus. Shared variants that never reached consensus (261 cases) were not phylogenetically associated. ### CONCLUSION Using robust methods to call within-host variants, we uncovered a consistent pattern of low within-host diversity, purifying selection, and narrow transmission bottlenecks. Within-host emergence of vaccine and therapeutic escape mutations is likely to be relatively rare, at least during early infection, when viral loads are high, but the observation of immune-escape variants in high-viral-load samples underlines the need for continued vigilance. ![Figure][2] Diagram showing low SARS-CoV-2 within-host genetic diversity and narrow transmission bottleneck. Individuals with high viral load typically have few, if any, within-host variants. Narrow transmission bottlenecks mean that the major variant in the source individual was typically transmitted and the minor variants lost. Occasionally, the minor variant was transmitted, leading to a consensus change, or multiple variants were transmitted, resulting in a mixed infection. Credit: FontAwesome, licensed under CC BY 4.0. Extensive global sampling and sequencing of the pandemic virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have enabled researchers to monitor its spread and to identify concerning new variants. Two important determinants of variant spread are how frequently they arise within individuals and how likely they are to be transmitted. To characterize within-host diversity and transmission, we deep-sequenced 1313 clinical samples from the United Kingdom. SARS-CoV-2 infections are characterized by low levels of within-host diversity when viral loads are high and by a narrow bottleneck at transmission. Most variants are either lost or occasionally fixed at the point of transmission, with minimal persistence of shared diversity, patterns that are readily observable on the phylogenetic tree. Our results suggest that transmission-enhancing and/or immune-escape SARS-CoV-2 variants are likely to arise infrequently but could spread rapidly if successfully transmitted. [1]: /lookup/doi/10.1126/science.abg0821 [2]: pending:yes
April 14, 2021
BioSpace
Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities - read this article along with other careers information, tips and advice on BioSpace
April 14, 2021
BioSpace
Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities - read this article along with other careers information, tips and advice on BioSpace
April 12, 2021
BioSpace
Twist Bioscience Exercises Option to Purchase Custom Designed Antibody Library and Optimization Software - read this article along with other careers information, tips and advice on BioSpace
BioSpace
April 7, 2021
BioSpace
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience's innovative antibody discovery and optimization services as well as its unique "Library of Libraries" for biologics discovery.
Angus Liu
November 24, 2020
FierceBiotech
Single-domain antibodies, or "nanobodies," inspired by llamas, have been proposed as potential treatments for COVID-19. Twist Bioscience has two such candidates that the company plans to develop as nasal sprays, and they've shown early promise in animal models.
BioSpace
November 23, 2020
BioSpace
Twist Bioscience Corporation (Nasdaq: TWST) today announced preclinical data for three of its proprietary antibodies against the S1 protein in SARS-CoV-2, the virus that causes COVID-19.
BioSpace
November 19, 2020
BioSpace
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.
November 18, 2020
BioSpace
Twist Bioscience Ranked 60th Fastest Growing Company in North America on Deloitte's 2020 Fast 500TM - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE

References

Page 1 of 4
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.